Skip to main content
SpringerLink
Log in
Book cover

T-Cell Lymphomas pp 87–103Cite as

NK-Cell Neoplasms

  • Chapter
  • First Online:

  • 1259 Accesses

Part of the book series: Contemporary Hematology ((CH))

Abstract

The 2008 World Health Organization classification recognizes two categories of natural killer (NK)-cell neoplasm: extranodal NK/T-cell lymphoma, nasal type (ENKL), and aggressive NK-cell leukemia. The recognition of these disease entities and improvements in diagnostic procedures during the 1990s have facilitated large retrospective studies and prospective trials of novel treatments. Concurrent chemoradiotherapy using multidrug resistance non-related agents and etoposide is currently recommended as the standard of care for localized nasal NK/T-cell lymphoma because it is the only first-line treatment that has been found in prospective studies to be superior to radiotherapy alone. To improve the currently poor prognosis for patients with relapsed or refractory ENKL, international prospective clinical trials of new chemotherapeutic regimens and the development of novel agents are ongoing.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Jaffe ES, Chan JK, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20:103–11.

    PubMed  CAS  Google Scholar 

  2. Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.

    Google Scholar 

  3. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.

    Google Scholar 

  4. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4  +  CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007;109:1720–7.

    PubMed  CAS  Google Scholar 

  5. Maeda T, Murata K, Fukushima T, et al. A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol. 2005;81:148–54.

    PubMed  Google Scholar 

  6. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113:3931–7.

    PubMed  CAS  Google Scholar 

  7. Kim TM, Lee SY, Jeon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol. 2008;19:1477–84.

    PubMed  CAS  Google Scholar 

  8. Tse E, Leung R, Khong PL, Lau WH, Kwong YL. Non-nasal natural killer cell lymphoma: not non-nasal after all. Ann Hematol. 2009;88:185–7.

    PubMed  Google Scholar 

  9. Takahashi E, Asano N, Li C, et al. Nodal T/NK-cell lymphoma of nasal type: a clinicopathological study of six cases. Histopathology. 2008;52:585–96.

    PubMed  CAS  Google Scholar 

  10. Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood. 2008;112:3057–64.

    PubMed  CAS  Google Scholar 

  11. Cerroni L, Massone C, Kutzner H, Mentzel T, Umbert P, Kerl H. Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein–Barr virus infection. Am J Surg Pathol. 2008;32:891–8.

    PubMed  Google Scholar 

  12. Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematop. 2005;45:51–70.

    Google Scholar 

  13. Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18:763–70.

    PubMed  CAS  Google Scholar 

  14. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501–13.

    PubMed  CAS  Google Scholar 

  15. Drenou B, Lamy T, Amiot L, et al. CD3- CD56+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood. 1997;89:2966–74.

    PubMed  CAS  Google Scholar 

  16. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93:599–606.

    PubMed  CAS  Google Scholar 

  17. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139:532–44.

    PubMed  CAS  Google Scholar 

  18. Ohno Y, Amakawa R, Fukuhara S, et al. Acute transformation of chronic large granular lymphocyte leukemia associated with additional chromosome abnormality. Cancer. 1989;64:63–7.

    PubMed  CAS  Google Scholar 

  19. Nakashima Y, Tagawa H, Suzuki R, et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005;44:247–55.

    PubMed  CAS  Google Scholar 

  20. Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010;21:1032–40.

    PubMed  CAS  Google Scholar 

  21. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–8.

    PubMed  Google Scholar 

  22. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–94.

    Google Scholar 

  23. Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685–90.

    PubMed  CAS  Google Scholar 

  24. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-PET with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652–9.

    PubMed  Google Scholar 

  25. Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87:613–21.

    PubMed  Google Scholar 

  26. Karantanis D, Subramaniam RM, Peller PJ, et al. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma. 2008;8:94–9.

    PubMed  Google Scholar 

  27. Lee J, Suh C, Huh J, et al. Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res. 2007;13:3250–4.

    PubMed  CAS  Google Scholar 

  28. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:717–20.

    PubMed  CAS  Google Scholar 

  29. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.

    PubMed  Google Scholar 

  30. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int. 2000;50:696–702.

    Google Scholar 

  31. Harabuchi Y, Yamanaka N, Kataura A, et al. Epstein–Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990;335:128–30.

    PubMed  CAS  Google Scholar 

  32. Calderon-Garciduenas L, Delgado R, Calderon-Garciduenas A, et al. Malignant neoplasms of the nasal cavity and paranasal sinuses: a series of 256 patients in Mexico City and Monterrey. Is air pollution the missing link? Otolaryngol Head Neck Surg. 2000;122:499–508.

    PubMed  CAS  Google Scholar 

  33. Xu JX, Hoshida Y, Yang WI, et al. Life-style and environmental factors in the development of nasal NK/T-cell lymphoma: a case–control study in East Asia. Int J Cancer. 2007;120:406–10.

    PubMed  CAS  Google Scholar 

  34. Emile JF, Boulland ML, Haioun C, et al. CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood. 1996;87:1466–73.

    PubMed  CAS  Google Scholar 

  35. Hasserjian RP, Harris NL. NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype. Am J Clin Pathol. 2007;127:860–8.

    PubMed  CAS  Google Scholar 

  36. Yamaguchi M, Ohno T, Oka K, et al. Discordant reaction of Leu4 and rabbit anti-human CD3 epsilon in sinonasal “T”-cell lymphoma. Int J Hematol. 1993;59:25–30.

    PubMed  CAS  Google Scholar 

  37. Suzumiya J, Takeshita M, Kimura N, et al. Sinonasal malignant lymphoma of natural killer cell phenotype associated with diffuse pancreatic involvement. Leuk Lymphoma. 1993;10:231–6.

    PubMed  CAS  Google Scholar 

  38. Ohno T, Yamaguchi M, Oka K, Miwa H, Kita K, Shirakawa S. Frequent expression of CD3 epsilon in CD3 (Leu 4)-negative nasal T-cell lymphomas. Leukemia. 1995;9:44–52.

    PubMed  CAS  Google Scholar 

  39. Chan JK, Tsang WY, Pau MY. Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Hum Pathol. 1995;26:1139–43.

    PubMed  CAS  Google Scholar 

  40. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351–6.

    PubMed  CAS  Google Scholar 

  41. Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2007;109:2183–9.

    PubMed  CAS  Google Scholar 

  42. Shim SJ, Yang WI, Shin E, et al. Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys. 2007;67:31–8.

    PubMed  CAS  Google Scholar 

  43. Chiang AK, Tao Q, Srivastava G, Ho FC. Nasal NK- and T-cell lymphomas share the same type of Epstein–Barr virus latency as nasopharyngeal carcinoma and Hodgkin’s disease. Int J Cancer. 1996;68:285–90.

    PubMed  CAS  Google Scholar 

  44. Harabuchi Y, Takahara M, Kishibe K, Moriai S, Nagato T, Ishii H. Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features. Int J Clin Oncol. 2009;14:181–90.

    PubMed  CAS  Google Scholar 

  45. Kim JE, Kim YA, Jeon YK, Park SS, Heo DS, Kim CW. Comparative analysis of NK/T-cell lymphoma and peripheral T-cell lymphoma in Korea: clinicopathological correlations and analysis of EBV strain type and 30-bp deletion variant LMP1. Pathol Int. 2003;53:735–43.

    PubMed  CAS  Google Scholar 

  46. Takakuwa T, Dong Z, Nakatsuka S, et al. Frequent mutations of Fas gene in nasal NK/T cell lymphoma. Oncogene. 2002;21:4702–5.

    PubMed  CAS  Google Scholar 

  47. Takahara M, Kishibe K, Bandoh N, Nonaka S, Harabuchi Y. P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol. 2004;35:86–95.

    PubMed  CAS  Google Scholar 

  48. Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein–Barr virus. Blood. 2001;97:708–13.

    PubMed  CAS  Google Scholar 

  49. Takahara M, Kis LL, Nagy N, et al. Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. Int J Cancer. 2006;119:2775–83.

    PubMed  CAS  Google Scholar 

  50. Huang Y, de Reynies A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010;115:1226–37.

    PubMed  CAS  Google Scholar 

  51. Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-­suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 2011;118:3195–204.

    PubMed  CAS  Google Scholar 

  52. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216–21.

    PubMed  CAS  Google Scholar 

  53. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27:5594–600.

    PubMed  CAS  Google Scholar 

  54. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009;27:6027–32.

    PubMed  CAS  Google Scholar 

  55. Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106:3785–90.

    PubMed  CAS  Google Scholar 

  56. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein–Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol. 2000;111:239–46.

    PubMed  CAS  Google Scholar 

  57. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Diagnostic and prognostic implications of circulating cell-free Epstein–Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res. 2002;8:29–34.

    PubMed  CAS  Google Scholar 

  58. Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118:6018–22.

    Google Scholar 

  59. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1093–101.

    PubMed  Google Scholar 

  60. Yamaguchi M, Ogawa S, Nomoto Y, et al. Treatment outcome of nasal NK-cell lymphoma: A report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematop. 2001;41:93–9.

    Google Scholar 

  61. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–6.

    PubMed  CAS  Google Scholar 

  62. Yu KH, Yu SC, Teo PM, Chan AT, Yeo W, Chow J. Nasal lymphoma: results of local radiotherapy with or without chemotherapy. Head Neck. 1997;19:251–9.

    PubMed  CAS  Google Scholar 

  63. Kwong YL, Chan AC, Liang R, et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol. 1997;97:821–9.

    PubMed  CAS  Google Scholar 

  64. Ribrag V, Ell Hajj M, Janot F, et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia. 2001;15:1123–6.

    PubMed  CAS  Google Scholar 

  65. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54:182–90.

    PubMed  Google Scholar 

  66. Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100:366–75.

    PubMed  Google Scholar 

  67. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15:618–25.

    PubMed  Google Scholar 

  68. Pagano L, Gallamini A, Trape G, et al. NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey. Ann Oncol. 2006;17:794–800.

    PubMed  CAS  Google Scholar 

  69. Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol. 2001;12:349–52.

    PubMed  CAS  Google Scholar 

  70. Lee SH, Ahn YC, Kim WS, Ko YH, Kim K, Park K. The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma. Haematologica. 2006;91:427–8.

    PubMed  Google Scholar 

  71. Huang H, Lin Z, Lin X, Cai Q, Xia Z, Jiang W. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen. Leuk Lymphoma. 2011;52:1041–8.

    Google Scholar 

  72. Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54–63.

    PubMed  CAS  Google Scholar 

  73. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181–9.

    PubMed  Google Scholar 

  74. Shikama N, Ikeda H, Nakamura S, et al. Localized aggressive non-Hodgkin’s lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys. 2001;51:1228–33.

    PubMed  CAS  Google Scholar 

  75. Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59:1127–37.

    PubMed  Google Scholar 

  76. Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006;106:609–15.

    PubMed  Google Scholar 

  77. Tomita N, Kodaira T, Tachibana H, et al. A comparison of radiation treatment plans using IMRT with helical tomotherapy and 3D conformal radiotherapy for nasal natural killer/T-cell lymphoma. Br J Radiol. 2009;82:756–63.

    PubMed  CAS  Google Scholar 

  78. Kim SJ, Oh SY, Hong JY, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol. 2010;21:1058–63.

    PubMed  CAS  Google Scholar 

  79. Aviles A, Diaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol. 2000;22:215–20.

    PubMed  CAS  Google Scholar 

  80. Okamoto M, Maruyama F, Tsuzuki M, et al. Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki. 1994;35:635–41 (in Japanese).

    PubMed  CAS  Google Scholar 

  81. Uno M, Tsuchiyama J, Moriwaki A, et al. In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol. 2001;113:1009–14.

    PubMed  CAS  Google Scholar 

  82. Lee KW, Yun T, Kim DW, et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/− radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2006;47:1274–82.

    PubMed  CAS  Google Scholar 

  83. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19:2665–73.

    PubMed  CAS  Google Scholar 

  84. Au WY, Lie AK, Liang R, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol. 2003;14:1673–6.

    PubMed  CAS  Google Scholar 

  85. Girinsky T, Lapusan S, Ribrag V, Koscielny S, Ferme C, Carde P. Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas. Int J Radiat Oncol Biol Phys. 2005;61:476–9.

    PubMed  Google Scholar 

  86. Shimada K, Suzuki R. Concurrent chemoradiotherapy for limited-stage extranodal natural killer/T-cell lymphoma, nasal type. J Clin Oncol. 2010;28:e229. author reply e30.

    PubMed  Google Scholar 

  87. Kim HJ, Bang SM, Lee J, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant. 2006;37:819–24.

    PubMed  CAS  Google Scholar 

  88. Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14:1356–64.

    PubMed  Google Scholar 

  89. Aviles A, Cleto S, Castaneda C, Nambo MJ. CMED in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology. 2007;12:241–4.

    PubMed  CAS  Google Scholar 

  90. Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78:163–7.

    PubMed  CAS  Google Scholar 

  91. Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130:860–8.

    PubMed  CAS  Google Scholar 

  92. Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol. 2001;74:447–50.

    PubMed  CAS  Google Scholar 

  93. Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117:1834–9.

    PubMed  CAS  Google Scholar 

  94. Nowak-Gottl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003;101:2529–33.

    PubMed  CAS  Google Scholar 

  95. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99:1016–20.

    PubMed  CAS  Google Scholar 

  96. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410–6.

    Google Scholar 

  97. Liang R, Chen F, Lee CK, et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant. 1997;19:91–3.

    PubMed  CAS  Google Scholar 

  98. Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130:561–7.

    PubMed  Google Scholar 

  99. Suzuki R, Suzumiya J, Nakamura S, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006;37:425–31.

    PubMed  CAS  Google Scholar 

  100. Shen L, Au WY, Guo T, et al. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood. 2007;110:469–70.

    PubMed  CAS  Google Scholar 

  101. Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 2008;19:2079–83.

    PubMed  CAS  Google Scholar 

  102. Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145:173–9.

    PubMed  CAS  Google Scholar 

  103. O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27:4357–64.

    PubMed  Google Scholar 

  104. Hui KF, Chiang AK. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein–Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer. 2010;126:2479–89.

    PubMed  CAS  Google Scholar 

  105. O’Mahony D, Morris JC, Stetler-Stevenson M, et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res. 2009;15:2514–22.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan

    Motoko Yamaguchi

  2. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan

    Kensei Tobinai

Authors
  1. Motoko Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kensei Tobinai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Motoko Yamaguchi .

Editor information

Editors and Affiliations

  1. Yale University School of Medicine, Dept. of Medical Oncology/Hematology, Cedar Street 333, New Haven, 06520, Connecticut, USA

    Francine Foss

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Yamaguchi, M., Tobinai, K. (2013). NK-Cell Neoplasms. In: Foss, F. (eds) T-Cell Lymphomas. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-170-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-170-7_6

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-169-1

  • Online ISBN: 978-1-62703-170-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation